NCT07816341
F182112 in Relapsed/Refractory Autoimmune Hemolytic Anemia
StatusRecruiting
PhasePhase 1
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Recruitment opened
- Start date changed from estimate of Oct 10, 2026 to Oct 27, 2026
- Site details revised
- Study title shortened, about 4 words
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Incidence of adverse events
Timeframe: 28 days post the last dose treatment
Arms and interventions
F182112 in Relapsed/Refractory Autoimmune Hemolytic AnemiaExperimental
F182112 is a recombinant humanized anti-BCMA/CD3 bispecific antibody for injection. By binding to CD3 receptors on T cells, F182112 can effectively deplete BCMA-expressing B cells and plasma cells in vivo, thereby alleviating the clinical manifestations of autoimmune diseases.
Drugs: F182112 single-agent
Sites
1 site in 1 country
- Red Blood Cell Diseases Center and Regenerative Medicine CenterTianjin, Tianjin Municipality, China